AIA
XBI icon

Avalon Investment & Advisory’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Avalon Investment & Advisory’s Portfolio XBI Stock Details XBI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		$1.61M Sell
21,149
-815
-4% -$67.6K 0.04% 178
2022
Q4 		$1.82M Sell
21,964
-253
-1% -$20.5K 0.05% 172
2022
Q3 		$1.76M Sell
22,217
-1,393
-6% -$117K 0.05% 169
2022
Q2 		$1.75M Sell
23,610
-885
-4% -$66.4K 0.05% 172
2022
Q1 		$2.2M Buy
24,495
+2,765
+13% +$255K 0.05% 166
2021
Q4 		$2.43M Sell
21,730
-3,623
-14% -$437K 0.06% 161
2021
Q3 		$3.19M Buy
25,353
+664
+3% +$85.5K 0.07% 166
2021
Q2 		$3.34M Buy
24,689
+2,153
+10% +$283K 0.07% 168
2021
Q1 		$3.06M Buy
22,536
+893
+4% +$134K 0.07% 166
2020
Q4 		$3.05M Sell
21,643
-582
-3% -$74.5K 0.06% 173
2020
Q3 		$2.48M Sell
22,225
-3,004
-12% -$337K 0.06% 169
2020
Q2 		$2.82M Sell
25,229
-7,316
-22% -$721K 0.07% 166
2020
Q1 		$2.52M Sell
32,545
-1,731
-5% -$153K 0.06% 180
2019
Q4 		$3.26M Sell
34,276
-194
-0.6% -$16.8K 0.07% 184
2019
Q3 		$2.63M Sell
34,470
-440
-1% -$36.6K 0.06% 190
2019
Q2 		$3.06M Buy
34,910
+314
+0.9% +$26.8K 0.07% 182
2019
Q1 		$3.13M Buy
34,596
+248
+0.7% +$21.1K 0.07% 182
2018
Q4 		$2.46M Buy
34,348
+1,765
+5% +$142K 0.06% 193
2018
Q3 		$3.12M Buy
32,583
+2,272
+7% +$220K 0.09% 204
2018
Q2 		$2.88M Sell
30,311
-6,977
-19% -$641K 0.09% 195
2018
Q1 		$3.27M Buy
37,288
+3,527
+10% +$322K 0.1% 162
2017
Q4 		$2.87M Buy
33,761
+1,129
+3% +$94.6K 0.09% 170
2017
Q3 		$2.83M Sell
32,632
-247
-0.8% -$19.8K 0.09% 161
2017
Q2 		$2.54M Buy
32,879
+427
+1% +$30.3K 0.08% 169
2017
Q1 		$2.25M Buy
32,452
+3,158
+11% +$212K 0.08% 173
2016
Q4 		$1.73M Buy
29,294
+108
+0.4% +$6.67K 0.06% 178
2016
Q3 		$1.94M Buy
+29,186
New +$1.81M 0.07% 149

Other funds holding XBI

Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Avalon Investment & Advisory's XBI Position: Q1 2023 in Review

Avalon Investment & Advisory reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 3.7% in Q1 2023, selling an estimated $67.6K and leaving 21,149 shares worth $1.61M. The position accounts for 0.04% of the portfolio, ranked #178.

Avalon Investment & Advisory first reported a position in XBI in Q3 2016 and has held it in 27 quarters since. The position peaked at $3.34M in Q2 2021. 712 funds tracked by Wall St. Rank hold XBI as of Q1 2023.

  • Avalon Investment & Advisory held 21,149 shares of State Street SPDR S&P Biotech ETF worth $1.61M as of Q1 2023.
  • Avalon Investment & Advisory sold 815 State Street SPDR S&P Biotech ETF shares in Q1 2023, an estimated $67.6K.
  • State Street SPDR S&P Biotech ETF made up 0.04% of Avalon Investment & Advisory's portfolio in Q1 2023, its #178 holding.
  • Avalon Investment & Advisory first reported a position in State Street SPDR S&P Biotech ETF in Q3 2016 and has held it in 27 quarters since.
  • Avalon Investment & Advisory's State Street SPDR S&P Biotech ETF position peaked at $3.34M in Q2 2021.
  • 712 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2023.

Based on Avalon Investment & Advisory's 13F filing for Q1 2023, filed 15 May 2023.